Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3002MR)

This product GTTS-WQ3002MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3002MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1548MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13596MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ11074MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ10209MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ8718MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ12462MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ7135MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ2451MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 157
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW